Adma Biologics Inc
ADMA
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.29B
Close$
$7.07
27.7% downside
Current Fair Value
27.7% downsideOvervalued by 27.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.29 Billion |
|---|---|
| Enterprise Value | $2.36 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.62 |
| Beta | 0.73 |
| Outstanding Shares | 228,232,503 |
Return
| Return on Equity | 41.39% |
|---|---|
| Return on Assets | 24.69% |
| Return on Invested Capital | 37.17% |
Valuation & Multiples
| P/E Ratio | 13.75 |
|---|---|
| PEG | 130.59 |
| Price to Sales | 4.89 |
| Price to Book Ratio | 9.78 |
| Enterprise Value to Revenue | 4.61 |
| Enterprise Value to EBIT | 10.45 |
| Enterprise Value to Net Income | 13 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.5 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$0.22
Average shareholder expectationRevenue Estimate
$149.08 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$0.19
Average shareholder expectationRevenue Estimate
$138.12 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 34.77% |
|---|---|
| Total Calls | 510▼ 99.99% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 28.01%▼ 61.73% |
|---|---|
| Total Invested | $553.61M▼ 71.05% |
| Investors Holding | 132▼ 241.00% |
ESG Score
No data